Tower Research Capital LLC (Trc) Larimar Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,287 shares of LRMR stock, worth $14,490. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,287
Previous 5,839
26.58%
Holding current value
$14,490
Previous $16,000
18.75%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding LRMR
# of Institutions
155Shares Held
89MCall Options Held
6.44MPut Options Held
622K-
Deerfield Management Company, L.P. (Series C) New York, NY30.6MShares$103 Million1.84% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20.4 Million0.34% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.85MShares$19.8 Million8.2% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.9MShares$16.6 Million0.01% of portfolio
-
Opaleye Management Inc. Boston, MA3.72MShares$12.6 Million2.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $146M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...